A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease

Clicks: 464
ID: 269350
2005
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #1 of 10 articles by views in alimentary pharmacology & therapeutics

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The CDP571 was effective for corticosteroid-sparing at week 16 but not week 10, and was well-tolerated in patients with corticosteroid-dependent Crohn's disease.
Reference Key
bg2005alimentarya Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Feagan BG;Sandborn WJ;Baker JP;Cominelli F;Sutherland LR;Elson CO;Salzberg BA;Archambault A;Bernstein CN;Lichtenstein GR;Heath PK;Cameron S;Hanauer SB;;
Journal alimentary pharmacology & therapeutics
Year 2005
DOI
DOI not found
URL
https://www.pubmed.gov/15709987/
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't adult female male middle aged Drug Administration Schedule Clinical Trial Randomized Controlled Trial Antibodies Monoclonal / therapeutic use* Double-Blind Method severity of illness index Gastrointestinal Agents / therapeutic use* monoclonal / adverse effects crohn disease / drug therapy* anti-inflammatory agents non-steroidal / therapeutic use* phase ii anti-inflammatory agents / adverse effects quality of life tumor necrosis factor-alpha / antagonists & inhibitors anti-inflammatory agents / administration & dosage prednisolone / administration & dosage crohn disease / pathology pmid:15709987 doi:10.1111/j.1365-2036.2005.02336.x b g feagan w j sandborn s b hanauer budesonide / administration & dosage

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.